Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Research & Development (2016 - 2025)

Mimedx's Research & Development history spans 15 years, with the latest figure at $4.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 33.32% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $15.0 million, up 21.17%, while the annual FY2025 figure was $15.1 million, 22.33% up from the prior year.
  • Research & Development for Q4 2025 was $4.8 million at Mimedx, up from $3.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $11.5 million in Q2 2023 and bottomed at -$5.5 million in Q4 2023.
  • The 5-year median for Research & Development is $3.6 million (2024), against an average of $3.1 million.
  • The largest annual shift saw Research & Development plummeted 182.64% in 2021 before it surged 164.89% in 2024.
  • A 5-year view of Research & Development shows it stood at -$2.8 million in 2021, then tumbled by 66.6% to -$4.7 million in 2022, then dropped by 16.39% to -$5.5 million in 2023, then surged by 164.89% to $3.6 million in 2024, then soared by 33.32% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Research & Development are $4.8 million (Q4 2025), $3.7 million (Q3 2025), and $3.6 million (Q4 2024).